Opportunity
Peripheral nervous system (PNS) injuries, such as brachial plexus injuries and complete nerve transections, often result in slow axonal regrowth and suboptimal functional recovery, even after surgical repair. A major challenge is the identification of key genes that regulate the intrinsic growth program of damaged neurons to enable successful regeneration. Current understanding of epigenetic mechanisms, such as DNA methylation and histone modifications, in coordinating axonal regeneration remains incomplete and descriptive. While low-dose ionizing radiation (LDIR) has shown neuroprotective benefits and can enhance axonal regrowth, its precise molecular mechanisms are unclear. There is a pressing need for improved therapeutic strategies that can effectively accelerate axonal regeneration and functional recovery after neural injury.
Technology
This patent discloses the use of metaxalone or Formin-2 (Fmn2) inhibitors to treat neural injuries. The innovation is based on the discovery that Fmn2 acts as a negative regulator of axonal regeneration. Downregulation or inhibition of Fmn2 enhances microtubule dynamics in growth cones by increasing the displacement rate of microtubule end-binding protein 3 (EB3) comets and promotes axonal regrowth. Mechanistically, Fmn2 inhibition leads to upregulated phosphorylation of histone deacetylase 5 (HDAC5), which in turn reduces α-tubulin acetylation in regenerating axons, thereby increasing microtubule dynamics and facilitating regeneration. The patent identifies metaxalone, an FDA-approved small molecule, through bioinformatics analysis of Fmn2 knockout gene expression profiles. Metaxalone mimics the pro-regenerative effects of Fmn2 inhibition, promoting robust axonal regeneration and functional recovery in vivo, even when treatment is delayed by 24 hours post-injury.
Advantages
- Targets a novel mechanism: Fmn2 inhibition enhances microtubule dynamics, a key process in axonal regeneration.
- Utilizes an FDA-approved drug (metaxalone), facilitating faster clinical translation and reducing development timelines.
- Effective even with delayed treatment (up to 24 hours post-injury), offering a practical therapeutic window.
- Promotes both sensory and motor functional recovery after peripheral nerve injury.
- Specific neuronal targeting possible via AAV2/9-mediated delivery of Fmn2 inhibitors to DRG and motor neurons.
- Combines gene therapy (e.g., shRNA) and small-molecule approaches for flexible treatment strategies.
Applications
- Treatment of peripheral nerve injuries (e.g., brachial plexus injuries, sciatic nerve damage).
- Therapy for central nervous system injuries (e.g., spinal cord injury, traumatic brain injury).
- Potential application in neurodegenerative diseases where axonal regeneration is impaired.
- Use in surgical nerve repair to accelerate post-operative recovery.
- Development of pharmaceutical compositions containing metaxalone or Fmn2 inhibitors for neural repair.
- Gene therapy approaches using inhibitory nucleic acids (e.g., shRNA, siRNA) targeting Fmn2.
